Report Library
All Reports
IN VIVO Article: The Shrinking Value of Best-In-Class & First-In-Class Drugs
July 24, 2015
BioMedTracker is featuring content from respected outside sources to augment its original report content. This article was
originally published by IN VIVO, July/August 2015. IN VIVO is the premier strategic business resource for the biopharma, medtech, and
diagnostics industries.
For more information about IN VIVO, please visit IN VIVO here.
Incumbency ain’t worth what it once was. Pharma companies are spending billions to create advantages that won’t have significant
lasting power. Smart followers can do as well - for less.
For our disclosures, please read the BioMedTracker Research Standards.
- As payors struggle to control their spend on specialty drugs, they will be less likely to allow best- or first-in-class drug to gain dominant market shares.
- To do so, they are crafting strategies to restrict physicians from widespread prescribing of new, expensive drugs.
- For pharma, market incumbency will be far more difficult to achieve. Payor-friendly market followers who leverage the groundwork laid by their predecessors could achieve higher ROI.
For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: |
Autoimmune/immunology
Cardiovascular Infectious Disease |
| Indications Covered: |
Neuromyelitis Optica (Devic's Syndrome, NMO)
Wound Healing |
Additional Resources: